Invivyd, Inc. (NASDAQ:IVVD) Short Interest Update

Invivyd, Inc. (NASDAQ:IVVD - Get Free Report) was the target of a significant drop in short interest in September. As of September 30th, there was short interest totalling 6,810,000 shares, a drop of 8.0% from the September 15th total of 7,400,000 shares. Based on an average daily trading volume, of 438,400 shares, the days-to-cover ratio is presently 15.5 days. Currently, 9.4% of the shares of the company are sold short.

Invivyd Stock Up 3.6 %

IVVD traded up $0.03 during midday trading on Wednesday, reaching $0.99. 243,622 shares of the company's stock were exchanged, compared to its average volume of 652,048. The firm has a market capitalization of $117.61 million, a price-to-earnings ratio of -0.52 and a beta of 0.63. Invivyd has a one year low of $0.81 and a one year high of $5.20. The business has a 50-day simple moving average of $0.99 and a two-hundred day simple moving average of $1.58.

Invivyd (NASDAQ:IVVD - Get Free Report) last posted its earnings results on Wednesday, August 14th. The company reported ($0.40) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.37) by ($0.03). The firm had revenue of $2.26 million for the quarter, compared to the consensus estimate of $4.91 million. As a group, research analysts anticipate that Invivyd will post -0.6 EPS for the current fiscal year.

Institutional Inflows and Outflows

A number of institutional investors have recently modified their holdings of the company. Vanguard Group Inc. raised its stake in shares of Invivyd by 3.9% in the first quarter. Vanguard Group Inc. now owns 2,611,202 shares of the company's stock valued at $11,594,000 after acquiring an additional 97,496 shares during the last quarter. Marshall Wace LLP raised its stake in shares of Invivyd by 4.2% in the second quarter. Marshall Wace LLP now owns 786,899 shares of the company's stock valued at $866,000 after acquiring an additional 31,992 shares during the last quarter. Acadian Asset Management LLC raised its stake in shares of Invivyd by 232.0% in the second quarter. Acadian Asset Management LLC now owns 678,706 shares of the company's stock valued at $745,000 after acquiring an additional 474,301 shares during the last quarter. Duquesne Family Office LLC bought a new position in shares of Invivyd in the second quarter valued at approximately $629,000. Finally, Jacobs Levy Equity Management Inc. raised its stake in shares of Invivyd by 21.7% in the first quarter. Jacobs Levy Equity Management Inc. now owns 435,338 shares of the company's stock valued at $1,933,000 after acquiring an additional 77,603 shares during the last quarter. Institutional investors own 70.36% of the company's stock.

Analyst Ratings Changes

Separately, HC Wainwright restated a "buy" rating and set a $15.00 price target on shares of Invivyd in a research note on Tuesday, September 3rd.

Invivyd Company Profile

Invivyd, Inc, a commercial-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of antibody-based solutions for infectious diseases in the United States. The company developed INVYMAB, a platform that combines viral surveillance and predictive modeling with advanced antibody engineering.